Von Hippel-Lindau disease

Mayo Clinic Proceedings

Volumn 75, Issue 3, 2000, Pages 265-272

  Couch, Vicki ^a   Lindor, Noralane M ^a   Karnes, Pamela S ^a   Michels, Virginia V ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOSOMAL DOMINANT DISORDER; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; EPIDIDYMIS; GENOTYPE; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; MOLECULAR GENETICS; PANCREAS TUMOR; PHENOTYPE; PHEOCHROMOCYTOMA; REVIEW; SPINAL CORD TUMOR; VON HIPPEL LINDAU DISEASE;

EID: 0034095068     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.3.265     Document Type: Review

References (91)

1. McKusick VA. Mendelian Inheritance in Man: A Catalog of Human Genes and Genetic Disorders. 12th ed. Baltimore, Md: Johns Hopkins University Press; 1998.
2. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features [published correction appears in Radiology. 1995; 196:582]. Radiology. 1995; 194:629-642.
3. von Hippel E. Über eine sehr seltene Erkrankung der Netzhaut. Graefes Arch Clin Exp Ophthalmol. 1904;59:83-106.
4. Lindau A. Zur Frage der Angiomatosis retinae und ihrer Hirncomplikation. Acta Ophthalmol (Scand). 1927;4:193-226.
5. Melmon KL, Rosen SW. Lindau's disease: review of the literature and study of a large kindred. Am J Med. 1964;36:595-617.
6. Mäher ER, Iselius L, Yates JR, et al. von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28:443-447.
7. Neumann HP, Wiestier OD. Clustering of features of von HippelLindau syndrome: evidence for a complex genetic locus. Lancet. 1991;337:1052-1054.
8. Mäher ER. von Hippel-Lindau disease. Eur J Cancer. 1994; 30A:1987-1990.
9. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore). 1989;68:l-29.
10. Neumann HP, Lips CJ, Hsia YE, Zbar B. von Hippel-Lindau syndrome. Brain Pathol. 1995;5:181-193.
11. Filling-Katz MR, Choyke PL, Oldfield E, et al. Central nervous system involvement in von Hippel-Lindau disease. Neurology. 1991;41:41-46.
12. Mäher ER, Yates JR, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J MedGenei. 1990;27:311-314.
13. Linehan WM, Klausner RD. Renal carcinoma. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. New York, NY: McGraw-Hill; 1998:455-473.
14. Mäher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore). 1997;76:381-391.
15. Neumann HP, Eggert HR, Scheremet R, et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neural Neurosurg Psychiatry. 1992;55:898-901.
16. Karsdorp N, Elderson A, Wittebol-Post D, et al. von Hippel-Lindau disease: new strategies in early detection and treatment. Am J Med. 1994;97:158-168.
17. Filling-Katz MR, Choyke PL, Patronas NJ, et al. Radiologie screening for von Hippel-Lindau disease: the role of Gd-DTPA enhanced MR imaging of the CNS. J Comput Assist Tomogr. 1989; 13:743-755.
18. Neumann HP. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa. 1987; 16:220226.
19. Mäher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. QJM. 1990;77:1151-1163.
20. Green JS, Bowmer MI, Johnson GJ. von Hippel-Lindau disease in a Newfoundland kindred. CMAJ. 1986;134:133-138, 146.
21. Moore AT, Mäher ER, Rosen P, Gregor Z, Bird AC. Ophthalmological screening for von Hippel-Lindau disease. Eye. 1991;5:723728.
22. Ridley M, Green J, Johnson G. Retinal angiomatosis: the ocular manifestations of von Hippel-Lindau disease. Can J Ophthalmol. 1986;21:276-283.
23. Welch RB. von Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy. Trans Am Ophthalmol Soc. 1970;68:367424.
24. Glenn GM, Choyke PL, Zbar B, Linehan WM. von Hippel-Lindau disease: clinical review and molecular genetics. Probl Urol. 1990; 4:312-330.
25. Horton WA, Wong V, Eldridge R. von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members. Arch Intern Med. 1976;136:769-777.
26. Poston CD, Jaffe GS, Lubensky IA, et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol. 1995;153:22-26.
27. Solomon D, Schwartz A. Renal pathology in von Hippel-Lindau disease. Hum Pathol. 1988;19:1072-1079.
28. Richard S, Chauveau D, Chrétien Y, et al. Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol Necker Hosp. 1994;23:l-27.
29. Frimodt-Moller PC, Nissen HM, Dyreborg U. Polycystic kidneys as the renal lesion in Lindau's disease. J Urol. 1981;125:868-870.
30. Malek RS, Omess PJ, Benson RC Jr, Zincke H. Renal cell carcinoma in von Hippel-Lindau syndrome. Am J Med. 1987;82:236238.
31. Neumann HP. Prognosis of von Hippel-Lindau syndrome. Vasa. 1987:16:309-311.
32. Levine E, Collins DL, Horton WA, Schimke RN. CT screening of the abdomen in von Hippel-Lindau disease. AJR Am J Roentgenol. 1982:139:505-510.
33. Pearson JC, Weiss J, Tanagho EA. A plea for conservation of kidney in renal adenocarcinoma associated with von HippelLindau disease. J Urol. 1980; 124:910-912.
34. Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol. 1990; 144:852-857.
35. Frydenberg M, Malek RS, Zincke H. Conservative renal surgery for renal cell carcinoma in von Hippel-Lindau's disease. J Urol. 1993;149:461-464.
36. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995; 154:2010-2014.
37. Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease [published correction appears in N Engl J Med. 1994; 331:1535]. N Engl J Med. 1993:329:1531-1538.
38. Sato Y, Waziri M, Smith W, et al. Hippel-Lindau disease: MR imaging. Radiology. 1988; 166:241-246.
39. Atuk NO, McDonald T, Wood T, et al. Familial pheochromocytoma, hypercalcemia, and von Hippel-Lindau disease: a ten year study of a large family. Medicine (Baltimore). 1979;58:209218.
40. Reinig JW, Doppman JL, Dwyer AJ, Johnson AR, Knop RH. Adrenal masses differentiated by MR. Radiology. 1986; 158:8184.
41. van Gils AP, Falke TH, van Erkel AR, et al. MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas. Radiographies. 1991; 11:37-57.
42. Cryer PE. Phaeochromocytoma. Clin Endocrinol Melab. 1985; 14: 203-220.
43. Hull CJ. Phaeochromocytoma: diagnosis, preoperative preparation and anaesthetic management. Br J Anaesth. 1986;58:1453-1468.
44. Neumann HP, Dinkel E, Brambs H, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991; 101:465471.
45. Bickler S, Wile AG, Melicharek M, Recher L. Pancreatic involvement in Hippel-Lindau disease. West J Med. 1984:140:280-282.
46. Choyke PL, Filling-Katz MR, Shawker TH, et al. von HippelLindau disease: radiologie screening for visceral manifestations. Radiology. 1990; 174:815-820.
47. Choyke PL, Glenn GM, Walther MM, et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol. 1992; 159:1229-1234.
48. Witten FR, O'Brien DP III, Sewell CW, Wheatley JK. Bilateral clear cell papillary cystadenoma of the epididymides presenting as infertility: an early manifestation of von Hippel-Lindau's syndrome. J Urol. 1985:133:1062-1064.
49. Korn WT, Schatzki SC, DiSciullo AJ, Scully RE. Papillary cystadenoma of the broad ligament in von Hippel-Lindau disease. Am J Obstet Gynecol. 1990; 163:596-598.
50. Manski TJ, Heffner DK, Glenn GM, et al. Endolymphatic sac tumors: a source of morbid hearing loss in von Hippel-Lindau disease. JAMA. 1997:277:1461-1466.
51. Seizinger BR, Smith DI, Filling-Katz MR. et al. Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of von Hippel Lindau disease. Proc Natl Acad Sei USA. 1991:88:2864-2868.
52. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutât. 1995;5:66-75.
53. Glavac D, Neumann HP, Wittke C, et al. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet. 1996; 98:271-280.
54. Mäher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996;33:328-332.
55. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc NatI Acad Sei US A. 1971;68:820-823.
56. Iliopoulos O, Kaelin WG Jr. The molecular basis of von HippelLindau disease. Mol Med. 1997;3:289-293.
57. Yao M, Latif F. Orcutt ML, et al. von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis. Hum Gener. 1993;92:605-614.
58. Tory K, Brauch H, Linehan M, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst. 1989;81:1097-1101.
59. Latif F, Tory K, Gnarra J, et al. Identification of the von HippelLindau disease tumor suppressor gene. Science. 1993;260:13171320.
60. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:8590.
61. Richards FM, Schofield PN, Fleming S, Mäher ER. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet. 1996;5:639-644.
62. Kessler PM, Vasavada SP, Rackley RR, et al. Expression of the von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med. 1995; 1:457-466.
63. Crossey PA, Richards FM, Foster K. et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994:3:1303-1308.
64. Richards FM, Crossey PA, Phipps ME, et al. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet. 1994:3:595-598.
65. Whaley JM, Naglich J, Gelbert L, et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma [published correction appears in Am J Hum Genet. 1995:56:356]. Am J Hum Genet. 1994:55:1092-1102.
66. Decker HJ, Neuhaus C, Jauch A, et al. Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation: a combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH. Hum Genet. 1996:97:770-776.
67. Brauch H, Kishida T, Glavac D, et al. von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet. 1995:95:551 556.
68. Richards FM, Phipps ME. Latif F, et al. Mapping the von HippelLindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Hum Mol Genet. 1993:2:879-882.
69. Kishida T, Yao M, Chen F, Orcutt ML, Lerman MI, Zbar B. A novel donor splice site mutation associated with two mRNAs in von Hippel-Lindau disease. Hum Mol Genet. 1994;3:1191-1192.
70. Loeb DB, Pericak-Vance MA, Stajich JM, Vance JM. A novel mutation in the von Hippel-Lindau gene. Hum Mol Genet. 1994;3: 1423-1424.
71. Shuin T. Kondo K, Kaneko S, et al. Results of mutation analyses of von Hippel-Lindau disease gene in Japanese patients: comparison with results in United States and United Kingdom [in Japanese]. Hinyokika Kiyo. 1995;41:703-707.
72. Zbar B, Kishida T, Chen F, et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutât. 1996:8:348-357.
73. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995;1: 822-826.
74. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997:28:459-464.
75. Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc NatlAcadSci USA. 1996;93:1770-1775.
76. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest. 1996;75:231-238.
77. Duan DR, Humphrey JS, Chen DY, et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl AcadSciUSA. 1995;92:6459-6463.
78. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995; 269:1444-1446.
79. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res. 1995;55:4544-4548.
80. Tsuchiya H, Iseda T, Hino O. Identification of a novel protein (VB P-l) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res. 1996;56:2881-2885.
81. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 1995;269:1402-1406.
82. Aso T, Lane WS, Conaway JW, Conaway RC. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science. 1995;269:1439-1443.
83. Decker HJ, Weidt EJ, Brieger J. The von Hippel-Lindau tumor suppressor gene: a rare and intriguing disease opening new insight
84. into basic mechanisms of carcinogenesis. Cancer Genet Cytogenet. 1997;93:74-83.
85. Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat. 1995;36:139-155.
86. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54:4233-4237.
87. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 1995;55:1358-1364.
88. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 1995; 270:19761-19766.
89. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sei USA. 1996;93: 10589-10594.
90. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von HippelLindau protein. Proc Natl Acad Sei USA. 1996;93:10595-10599.
91. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von HippelLindau tumor suppressor protein. Cancer Res. 1996;56:22992301.